Details
Stereochemistry | ACHIRAL |
Molecular Formula | C48H66N5O10.2C2H3O2.Gd |
Molecular Weight | 1148.4 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Gd+3].CC([O-])=O.CC([O-])=O.CCC1=C2[N-]C(C=C3N=C(\C=N\C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4\N=C\C5=NC(=C2)C(CCCO)=C5C)C(C)=C3CCCO)=C1CC
InChI
InChIKey=VAZLWPAHMORDGR-WRIGXHCHSA-L
InChI=1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2/b39-27-,40-28-,41-27-,42-28-,45-31-,46-32-,49-31+,49-43+,50-32+,50-44+;;;
Motexafin gadolinium is a novel, MRI-detectable, an anticancer agent that enhances the cytotoxic potential of radiation therapy through several mechanisms, including depleting intracellular reducing metabolites that are necessary for repairing the oxidative damage induced by irradiation. Motexafin gadolinium catalyzes the oxidation of intracellular reducing metabolites such as ascorbate, glutathione, nicotinamide adenine dinucleotide phosphate, and protein thiols, generating reactive oxygen species in a process known as futile redox cycling. The depletion (through oxidation) of these reducing metabolites removes the substrate necessary in a cell to repair oxidative damage induced by radiation and, left unrepaired, such radiation-induced oxidative DNA damage is converted into lethal double-stranded breaks. Motexafin gadolinium has tumor-specific uptake, normal tissue sparing, and tolerable and reversible toxicities in clinical trials. Motexafin gadolinium use in conjunction with whole-brain radiation therapy (WBRT) has demonstrated an improvement in neurocognitive decline, neurologic progression, and quality of life in patients with brain metastases from Non-small-cell lung carcinoma. Motexafin gadolinium use in conjunction with radiosurgery and whole brain radiation therapy in the setting of brain metastases is currently being studied, as is Motexafin gadolinium with radiation and temozolomide in patients with glioblastoma multiforme.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. | 2005 Dec 15 |
|
Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. | 2005 May 1 |
|
Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities. | 2007 Jan |
|
Motexafin gadolinium: a novel radiosensitizer for brain tumors. | 2007 Jun |
|
Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines. | 2010 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00003563
5.0 mg/kg + 3 Gy of WBRT daily for a total of 10 days
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
246252-06-2
Created by
admin on Sat Dec 16 09:00:41 GMT 2023 , Edited by admin on Sat Dec 16 09:00:41 GMT 2023
|
PRIMARY | |||
|
50161
Created by
admin on Sat Dec 16 09:00:41 GMT 2023 , Edited by admin on Sat Dec 16 09:00:41 GMT 2023
|
PRIMARY | |||
|
m7637
Created by
admin on Sat Dec 16 09:00:41 GMT 2023 , Edited by admin on Sat Dec 16 09:00:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
12047567
Created by
admin on Sat Dec 16 09:00:41 GMT 2023 , Edited by admin on Sat Dec 16 09:00:41 GMT 2023
|
PRIMARY | |||
|
50162
Created by
admin on Sat Dec 16 09:00:41 GMT 2023 , Edited by admin on Sat Dec 16 09:00:41 GMT 2023
|
PRIMARY | |||
|
0BG5NE3APZ
Created by
admin on Sat Dec 16 09:00:41 GMT 2023 , Edited by admin on Sat Dec 16 09:00:41 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD